 |
|
semaxanib
A quinolone derivative with potential antineoplastic activity. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonym: | | semoxind | | | | Code names: | | SU5416
Sugen 5416 | | | | Chemical structure name: | | 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one | | |
|
|
